According to a recent LinkedIn post from Hemanext, the U.S. FDA has granted 510(k) clearance for expanded indications for the Hemanext ONE® system. The post indicates that the device can now be used to process AS-3 leukocyte-reduced red blood cells (RBCs) from whole blood or apheresis collections within 72 hours of collection.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post suggests this broader clearance could make it easier for blood centers to integrate hypoxic RBC processing into existing workflows. For investors, this may signal incremental regulatory de-risking, potential for higher adoption in transfusion medicine settings, and a stronger competitive position in blood-processing technologies.
By highlighting the upcoming America’s Blood Centers Annual Meeting in Tucson, the post also points to Hemanext’s efforts to engage directly with key decision-makers in blood centers. Increased visibility with this stakeholder group could support future commercial traction if centers choose to incorporate Hemanext ONE® into routine operations.
The reference to formal Instructions for Use and a dedicated press release suggests that a more detailed clinical and commercial narrative is being built around the product. If the expanded indication translates into higher utilization rates, Hemanext could see an improved revenue outlook over time, although the post does not provide any financial guidance or adoption metrics.